Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: Secondary analysis of the Euro-Ewing99-R1 trial.

Research output: Contribution to journalArticle

Abstract

Based on the randomised Euro-EWING99-R1 trial, vincristine, adriamycin, cyclophosphamide (VAC) may be able to replace vincristine, adriamycin, ifosfamide (VAI) in the treatment of standard-risk Ewing sarcoma. However some heterogeneity of treatment effect by gender was observed. The current exploratory study aimed at investigating the influence of gender on treatment efficacy and acute toxicity.

Details

Authors
  • Henk van den Berg
  • Michael Paulussen
  • Gwénaël Le Teuff
  • Ian Judson
  • Hans Gelderblom
  • Uta Dirksen
  • Bernadette Brennan
  • Jeremy Whelan
  • Ruth Lydia Ladenstein
  • Perrine Marec-Berard
  • Jarmila Kruseova
  • Lars Hjorth
  • Thomas Kühne
  • Benedicte Brichard
  • Keith Wheatley
  • Alan Craft
  • Heribert Juergens
  • Nathalie Gaspar
  • Marie-Cécile Le Deley
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Cancer and Oncology
Original languageEnglish
Pages (from-to)2453-2464
JournalEuropean Journal of Cancer
Volume51
Issue number16
Publication statusPublished - 2015
Publication categoryResearch
Peer-reviewedYes